Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14164164 | 0.76 | CHRNB4 (0.38) | ALDH1A1RAB9ANPC1MAPK1NOTUM | |
| SCHEMBL17327925 | 0.69 | KDM4E (0.36) | RAB9ANPC1MEN1KMT2A | |
| SCHEMBL14577595 | 0.69 | TDO2 (0.38) | ALDH1A1NOTUM | |
| SCHEMBL22036678 | 0.68 | L3MBTL1 (0.31) | — | |
| SCHEMBL15828042 | 0.64 | HSD11B1 (0.36) | ALDH1A1RAB9ANPC1MAPK1NOTUM | |
| SCHEMBL21239628 | 0.61 | NPC1 (0.33) | ALDH1A1RAB9ANPC1NOTUMKMT2A | |
| SCHEMBL24051253 | 0.60 | L3MBTL1 (0.35) | ALDH1A1RAB9ANPC1NOTUMMEN1 | |
| SCHEMBL23992680 | 0.60 | NPC1 (0.32) | RAB9ANPC1MAPK1 | |
| Biphenyl SCHEMBL30086255 | 0.59 | ALDH1A1 (0.90) | ALDH1A1RAB9ANPC1MAPK1NOTUM | |
| Biphenyl SCHEMBL28794039 | 0.59 | ALDH1A1 (0.90) | ALDH1A1RAB9ANPC1MAPK1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112282-A1 | IDO INHIBITORS AND THERAPEUTIC USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. | 2011-05-12 | — | — | US | disclosed |
| US-20110112282-A1 | IDO INHIBITORS AND THERAPEUTIC USES THEREOF | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112282-A1 | IDO INHIBITORS AND THERAPEUTIC USES THEREOF | IDO1, IDO2, IDH3B | ALDH1A1 3147/4885RAB9A 3597/4885NPC1 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.